Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts.

Yoshii Y, Yoshimoto M, Matsumoto H, Furukawa T, Zhang MR, Inubushi M, Tsuji AB, Fujibayashi Y, Higashi T, Saga T.

Oncotarget. 2017 Sep 28;8(51):88815-88826. doi: 10.18632/oncotarget.21323. eCollection 2017 Oct 24.

2.

Revision of the concept of anti-angiogenesis and its applications in tumor treatment.

Yang WH, Xu J, Mu JB, Xie J.

Chronic Dis Transl Med. 2017 Mar 8;3(1):33-40. doi: 10.1016/j.cdtm.2017.01.002. eCollection 2017 Mar 25. Review.

3.

Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.

Totzeck M, Mincu RI, Rassaf T.

J Am Heart Assoc. 2017 Aug 10;6(8). pii: e006278. doi: 10.1161/JAHA.117.006278. Review.

4.

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy.

Jiang C, Liu S, He W, Zhang B, Xia L.

J Cancer. 2017 May 12;8(8):1410-1416. doi: 10.7150/jca.18325. eCollection 2017.

5.

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

Sundar R, Chénard-Poirier M, Collins DC, Yap TA.

Front Med (Lausanne). 2017 Apr 10;4:39. doi: 10.3389/fmed.2017.00039. eCollection 2017. Review.

6.

Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis.

Quan Q, Huang Y, Chen Q, Qiu H, Hu Q, Rong Y, Li T, Xia L, Zhang B.

Transl Oncol. 2017 Apr;10(2):288-294. doi: 10.1016/j.tranon.2017.01.006. Epub 2017 Mar 2.

7.

Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis.

Yi S, Zeng L, Kuang Y, Cao Z, Zheng C, Zhang Y, Liao M, Yang L.

Onco Targets Ther. 2017 Feb 17;10:973-984. doi: 10.2147/OTT.S119879. eCollection 2017.

8.

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.

Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C.

Oncotarget. 2017 Mar 7;8(10):16887-16898. doi: 10.18632/oncotarget.14810.

9.

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.

Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G.

Oncotarget. 2017 Feb 7;8(6):9174-9188. doi: 10.18632/oncotarget.13942.

10.

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.

De Rosa M, Rega D, Costabile V, Duraturo F, Niglio A, Izzo P, Pace U, Delrio P.

Therap Adv Gastroenterol. 2016 Nov;9(6):861-886. Epub 2016 Aug 7. Review.

11.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi: 10.1007/s10549-016-3889-6. Epub 2016 Jul 8.

12.

Histopathological investigation of glioblastomas resected under bevacizumab treatment.

Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetrean O, Kono M, Mizutani K, Yamamoto Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H.

Oncotarget. 2016 Aug 9;7(32):52423-52435. doi: 10.18632/oncotarget.9387.

13.
14.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A.

Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612.

15.

Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling.

Singh NK, Kotla S, Kumar R, Rao GN.

EBioMedicine. 2015 Sep 28;2(11):1767-84. doi: 10.1016/j.ebiom.2015.09.042. eCollection 2015 Nov.

16.

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.

Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, Brinkmann U, Weidner KM, Regula J, Klein C.

MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.

17.

Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.

Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW.

World J Gastroenterol. 2016 Feb 7;22(5):1745-55. doi: 10.3748/wjg.v22.i5.1745. Review.

18.

Profile of bevacizumab and its potential in the treatment of cervical cancer.

Fisher CM, Schefter TE.

Onco Targets Ther. 2015 Nov 19;8:3425-31. doi: 10.2147/OTT.S73251. eCollection 2015. Review.

19.

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Niyazi M, Harter PN, Hattingen E, Rottler M, von Baumgarten L, Proescholdt M, Belka C, Lauber K, Mittelbronn M.

Oncotarget. 2016 Jan 19;7(3):2313-28. doi: 10.18632/oncotarget.6320. Review.

20.

Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.

Paiva TF Jr, de Jesus VH, Marques RA, da Costa AA, de Macedo MP, Peresi PM, Damascena A, Rossi BM, Begnami MD, de Lima VC.

BMC Cancer. 2015 Sep 22;15:643. doi: 10.1186/s12885-015-1648-4.

Supplemental Content

Support Center